KLP Kapitalforvaltning AS Purchases Shares of 6,400 TransMedics Group, Inc. (NASDAQ:TMDX)

KLP Kapitalforvaltning AS acquired a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 6,400 shares of the company’s stock, valued at approximately $399,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Principal Financial Group Inc. raised its stake in shares of TransMedics Group by 260.1% in the 3rd quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock valued at $31,759,000 after purchasing an additional 146,115 shares during the period. State of Michigan Retirement System bought a new position in shares of TransMedics Group during the fourth quarter worth about $6,734,000. Raymond James Financial Inc. acquired a new stake in TransMedics Group in the 4th quarter valued at approximately $3,845,000. Baillie Gifford & Co. lifted its stake in TransMedics Group by 14.9% in the 4th quarter. Baillie Gifford & Co. now owns 269,836 shares of the company’s stock valued at $16,824,000 after acquiring an additional 34,947 shares in the last quarter. Finally, Vaughan Nelson Investment Management L.P. lifted its stake in TransMedics Group by 9.9% in the 4th quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company’s stock valued at $22,547,000 after acquiring an additional 32,605 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Trading Down 4.6 %

Shares of TMDX opened at $67.67 on Friday. The firm has a market cap of $2.28 billion, a P/E ratio of 71.99 and a beta of 2.14. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The business has a 50-day moving average of $70.07 and a 200 day moving average of $85.74.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Canaccord Genuity Group restated a “buy” rating and set a $104.00 target price on shares of TransMedics Group in a report on Tuesday, March 11th. Robert W. Baird decreased their price objective on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a report on Wednesday, March 26th. JPMorgan Chase & Co. restated a “neutral” rating and issued a $75.00 price target (down from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Finally, Piper Sandler dropped their price objective on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, TransMedics Group has a consensus rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.